Unleashing a New Era in Neuroblastoma Treatment: The Promise of Lutetium-177 DTPA-Omburtamab
Summary: Neuroblastoma remains one of the most challenging paediatric cancers to treat, driving researchers and clinicians to explore highly targeted […]
Radiotherapeutics
The landscape of medical radiotherapeutics is rapidly evolving, showcasing a multitude of innovative treatments that target specific cancers and related symptoms with unprecedented precision. Utilising various radionuclides, these therapies represent a new frontier in the fight against cancer, offering hope for more effective and personalised treatment options.
Central to this advancement is the use of Actinium-225 (Ac-225), an alpha-emitting radionuclide, in a range of promising therapies. Alpha particles, with their high energy and short range, are effective in destroying cancer cells while minimising collateral damage to surrounding healthy tissues.
For instance, Ac-225-DOTA-SP targets Substance P receptors in glioblastoma, a notably aggressive brain tumour, delivering alpha radiation directly to the tumour site. This targeted approach is echoed in Ac-225-DOTA-YS5 and Ac-225-FPI-2265, both aimed at treating prostate cancer through different mechanisms. Ac-225-DOTA-YS5 targets CD46 using monoclonal antibody IgG1, whereas Ac-225-FPI-2265 focuses on the Prostate-Specific Membrane Antigen (PSMA) with PSMA-I&T.
The targeting of neuroendocrine tumours (NETs) has also seen significant developments with agents like Ac-225-DOTATOC and Ac-225-RYZ101, which focus on somatostatin receptors, delivering alpha radiation precisely to tumour cells. Further, Ac-225-DOTAZOL for bone pain palliation in patients with bone metastases exemplifies the versatility of radiotherapeutics, directly targeting bone tissues to provide pain relief.
Beyond alpha emitters, beta-emitting radionuclides like Yttrium-90 (Y-90) and Lutetium-177 (Lu-177) are also making strides in radiotherapeutics. Y-90 is employed in treating hepatocellular carcinoma and non-Hodgkin’s lymphoma, while Lu-177 is used in therapies for prostate cancer and neuroendocrine tumours.
Expanding the repertoire, treatments like At-211-81C6 mAb (Neuradiab) target brain cancer by using Astatine-211, another alpha emitter, conjugated with the monoclonal antibody 81C6. Similarly, At-211-MABG, targeting adrenergic tissues, is being developed for conditions like paragangliomas and pheochromocytoma.
Furthermore, Radium-223 (Ra-223) in Radium Dichloride therapy stands out for its application in bone pain palliation, particularly for metastatic prostate cancer. This therapy mimics calcium and selectively targets bone metastases, delivering alpha radiation.
The field also sees the development of therapies like Iodine-131 (I-131) in various forms, such as I-131-Apamistamab (Iomab-B™) for acute lymphoblastic leukaemia and Hodgkin’s lymphoma and I-131-Metuximab for hepatocarcinoma. Each of these I-131-based therapies leverages the beta radiation emitted by I-131 to target specific cancer cells.
In conclusion, the diversity of radiotherapeutics, from alpha and beta emitters to different targeting mechanisms, underscores the remarkable progress in this field. These therapies are advancing and redefining cancer treatment, offering more precise, effective, and patient-tailored options. As research and clinical trials continue, these groundbreaking developments in radiotherapeutics are poised to significantly impact the future of cancer therapy.
You are here:
home »
Pioneering Radiotheranostics: Lutetium-177 DPI-4452 Ushers in a New Era for CAIX-Expressing Solid Tumours
Summary: Lutetium-177 DPI-4452 represents a groundbreaking advance in the field of radiotheranostics for the treatment of carbonic anhydrase IX (CAIX)-expressing
Bone Metastasis Therapy: The Emerging Potential of Lutetium-177 DOTAZOL in Prostate Cancer Care
Summary: Lutetium-177 DOTAZOL represents a promising new avenue in the treatment of bone metastases originating from prostate cancer and other
Neuroendocrine Tumour Therapy: The Rise of Lutetium-177 DOTA-EB-TATE
Summary: Lutetium-177 DOTA-EB-TATE represents a cutting-edge advancement in the treatment of neuroendocrine tumours (NETs), building on established peptide receptor radionuclide
Neuroendocrine Tumour Therapy: The Rise of Lutetium-177 DOTA-EB-TATE Read Post »
Lutetium-177 DOTA-EB-FAPi: Pioneering a New Era in Precision Oncology and Beyond
Summary: Lutetium-177 DOTA-EB-FAPi is an innovative addition to the fibroblast activation protein inhibitor (FAPi) family, demonstrating tremendous promise in both
Lutetium-177 DOTA-EB-FAPi: Pioneering a New Era in Precision Oncology and Beyond Read Post »
Lutetium-177 Debio 1124: A Second-Generation Theranostic Agent Targeting CCK2R-Expressing Tumours
Summary: Lutetium-177 Debio 1124 is a second-generation radiolabelled peptide analogue of minigastrin, designed for targeted radiotherapy of tumours expressing the
Lutetium-177 CTT1403: A Therapeutic Breakthrough in Prostate Cancer Treatment
Summary: Prostate cancer remains one of the most challenging malignancies to treat, especially in metastatic and castrate-resistant stages. Lutetium-177 CTT1403,
Lutetium-177 CTT1403: A Therapeutic Breakthrough in Prostate Cancer Treatment Read Post »
Exploring Lutetium-177 AMTG: A Novel Radiolabelled Bombesin Analogue for GRPR-Positive Tumours
Summary: Lutetium-177 AMTG, a radiolabelled bombesin (BBN) analogue developed at the Technical University of Munich, represents an innovative approach to
Iodine-131 Weimeisheng: Transforming Advanced Lung Cancer Treatment
Summary: Iodine-131 Weimeisheng (¹³¹I-Tumor Necrosis Therapy mAb Injection) is a radiolabelled chimeric monoclonal antibody that targets intracellular DNA. Originally developed
Iodine-131 Weimeisheng: Transforming Advanced Lung Cancer Treatment Read Post »
The Rise and Fall of Iodine-131 Tositumomab: Bexxar’s Story
Summary: Iodine-131 Tositumomab, a radiolabelled anti-CD20 monoclonal antibody marketed as Bexxar, was introduced in 2003 for the treatment of non-Hodgkin
The Rise and Fall of Iodine-131 Tositumomab: Bexxar’s Story Read Post »
Iodine-131 TM601: Targeting Tumours with Radiolabelled Peptides
Summary: Iodine-131 TM601 (131I-Chlorotoxin) is a synthetic radiolabelled peptide exhibiting anti-angiogenic activity, developed for treating primary tumours and metastases in
Iodine-131 TM601: Targeting Tumours with Radiolabelled Peptides Read Post »
Peptide Receptor Radionuclide Therapy (PRRT): A Breakthrough in Treating Gastroenteropancreatic Neuroendocrine Tumours
Peptide Receptor Radionuclide Therapy utilises radiopharmaceuticals to target somatostatin receptor-expressing tumours, improving treatment outcomes significantly
TLX101: A Pioneering Radiopharmaceutical for Glioma Diagnosis and Therapy
Summary: TLX101 (formerly known as ACD-101) is a groundbreaking small molecule derived from 4-Iodophenylalanine. This radiopharmaceutical is designed for both
TLX101: A Pioneering Radiopharmaceutical for Glioma Diagnosis and Therapy Read Post »
The Role of Iodine-131 Sodium Iodide in Thyroid Disease Diagnosis and Therapy
Summary: ¹³¹I-Sodium Iodide has been a cornerstone in the diagnosis and treatment of thyroid diseases, including carcinomas, since the early
The Role of Iodine-131 Sodium Iodide in Thyroid Disease Diagnosis and Therapy Read Post »
Iodine-131 RPS-001: A Promising Radiolabelled Molecule in Prostate Cancer Therapy
Summary: Iodine-131 RPS-001 (also known as 131I-MIP-1095) is a novel radiolabelled small molecule targeting the prostate-specific membrane antigen (PSMA) receptor,
Iodine-131 RPS-001: A Promising Radiolabelled Molecule in Prostate Cancer Therapy Read Post »
Iodine-131 Omburtamab: A Breakthrough in Neuroblastoma Therapy
Summary: 131I-Omburtamab is a radiolabelled monoclonal antibody showing promising results in treating neuroblastoma, particularly in cases with central nervous system
Iodine-131 Omburtamab: A Breakthrough in Neuroblastoma Therapy Read Post »
The Role of Iodine-131 Naxitamab (¹³¹I-3F8) in Treating Neuroblastoma and Other Cancers
Summary: Iodine-131 Naxitamab (¹³¹I-3F8) is a murine monoclonal antibody targeting the GD2 disialoganglioside, labelled with radioactive iodine-131. It has been
The Role of Iodine-131 Naxitamab (¹³¹I-3F8) in Treating Neuroblastoma and Other Cancers Read Post »
Iodine-131 Metuximab (Licartin): A Radiolabelled Antibody for Hepatocarcinoma Treatment
Summary: 131I-Metuximab, marketed under the brand name Licartin, is a radiolabelled murine antibody developed for the treatment of hepatocellular carcinoma
Iodine-131 Metuximab (Licartin): A Radiolabelled Antibody for Hepatocarcinoma Treatment Read Post »
Iodine-131 Lipiodol: A Re-Emerging Therapeutic Agent in Hepatocellular Carcinoma Treatment
Summary: 131I-Lipiodol, also known as 131I-Ethiodized Oil, is a therapeutic agent initially authorised in 1995 under the name Lipiocis®. After
Iodine-131 Iopofosine: A Novel Radiolabelled Alkyl Phosphocholine for Cancer Therapy
Summary: Iodine-131-Iopofosine (also known as 131I-CLR-131, 131I-CLR-1404, and 131I-NM404) is an innovative small molecule designed for cancer therapy. As an
Iodine-131 Iopofosine: A Novel Radiolabelled Alkyl Phosphocholine for Cancer Therapy Read Post »
Iodine-131 Iobenguane: A Radiopharmaceutical Revolution in Neuroendocrine Tumour Diagnosis and Therapy
Summary: Iodine-131 Iobenguane (131I-Metaiodobenzylguanidine or 131I-MIBG) is a radiopharmaceutical agent widely used in the detection and treatment of neuroendocrine tumours
Advances in Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumours
Peptide Receptor Radionuclide Therapy offers a targeted approach to treating neuroendocrine tumours, improving survival rates and quality of life.
Advances in Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumours Read Post »
Clinical Trials: Advancements in ALSYMPCA, NETTER-1, and VISION Therapies
This article reviews key Phase III clinical trials for ALSYMPCA, NETTER-1, and VISION therapies, highlighting advancements in cancer treatment.
Clinical Trials: Advancements in ALSYMPCA, NETTER-1, and VISION Therapies Read Post »
Biological Principles of Targeted Radionuclide Therapy for Cancer
Targeted Radionuclide Therapy for cancer delivers radioactive isotopes directly to tumour cells, maximising therapeutic effectiveness.
Biological Principles of Targeted Radionuclide Therapy for Cancer Read Post »
Breakthrough in Adrenal Cancer Diagnosis and Treatment: The Rise of Iodine-131 IMAZA and Iodine-123 IMAZA
Iodine-131 IMAZA innovatively binds to adrenal cortex enzymes, revolutionizing the treatment and imaging of adrenocortical carcinoma effectively.
Iodine-131 ICF01012: A Promising Diagnostic and Therapeutic Agent for Metastasised Melanomas
Iodine-131 ICF01012, targeting melanin receptors, shows promise in the fight against metastasised melanomas, heralding a new era in treatment.
Exploring Iodine-131 chTNT: A Beacon of Hope in Cancer Treatment
Iodine-131 chTNT, aiming to revolutionise oncology, shows promise in targeting and eradicating tumour cells with precision.
Exploring Iodine-131 chTNT: A Beacon of Hope in Cancer Treatment Read Post »
Exploring Iodine-131 CAM-H2 for Treating HER2-Expressing Cancers
Iodine-131 CAM-H2 heralds a new era in oncology, offering hope through precise targeting of HER2-expressing cancers with minimal side effects.
Exploring Iodine-131 CAM-H2 for Treating HER2-Expressing Cancers Read Post »
Exploring Iodine-131 BA52: A Novel Melanin-Targeted Therapy for Malignant Melanomas
Iodine-131 BA52, a melanin-binding therapeutic, offers new hope for patients with melanin-positive malignant melanomas.
Exploring Iodine-131 BA52: A Novel Melanin-Targeted Therapy for Malignant Melanomas Read Post »
The Role of Iodine-131 Apamistamab for Acute Myeloid Leukaemia
Targeting Blood Cancers: The Role of Iodine-131 Apamistamab in Revolutionising Treatment for AML and Beyond
The Role of Iodine-131 Apamistamab for Acute Myeloid Leukaemia Read Post »
Iodine-131 Monoclonal Antibody 81C6 Targets Glioma Cells
Iodine-131 Monoclonal Antibody 81C6 specifically targets glioma cells by honing in on the tenascin protein.
Iodine-131 Monoclonal Antibody 81C6 Targets Glioma Cells Read Post »
Holmium-166 Phytate Offers a Promising Treatment Option for Chronic Synovitis
Holmium-166 Phytate, initially developed for chronic synovitis, has shown significant promise in phase I/II clinical trials.
Holmium-166 Phytate Offers a Promising Treatment Option for Chronic Synovitis Read Post »
Holmium-166 Chitosan in Radiopharmaceutical Cancer Treatment
Holmium-166 Chitosan, a groundbreaking radiopharmaceutical, offers new hope in treating hepatocellular carcinoma with targeted therapy.
Holmium-166 Chitosan in Radiopharmaceutical Cancer Treatment Read Post »
The Role and Impact of Holmium-166 Microspheres in Brachytherapy
Holmium-166 microspheres, by delivering localized radiation, significantly enhance the therapeutic approach to inoperable liver cancer treatment.
The Role and Impact of Holmium-166 Microspheres in Brachytherapy Read Post »
Erbium-169 Citrate: A Revolution in Small Joint Arthritis Treatment
The innovative 169Er-Erbium Citrate therapy precisely targets small joints, significantly easing arthritis with minimal side effects.
Erbium-169 Citrate: A Revolution in Small Joint Arthritis Treatment Read Post »
Unlocking the Potential of Copper-67 SARTATE in Targeted Radiopharmaceutical Therapy
Copper-67 SARTATE emerges as a groundbreaking radiopharmaceutical in targeted cancer therapy, showcasing promising clinical trial results.
Unlocking the Potential of Copper-67 SARTATE in Targeted Radiopharmaceutical Therapy Read Post »
Copper-67 SARbisPSMA New Frontier in Prostate Cancer Treatment
Copper-67 SARbisPSMA offers new hope in targeting and treating prostate cancer with precision and effectiveness.
Copper-67 SARbisPSMA New Frontier in Prostate Cancer Treatment Read Post »
Unlocking New Horizons in Glioblastoma Treatment: The Potential of Copper-64 Diasparagine
Copper-64 Diasparagine offers a promising breakthrough in targeting and treating aggressive brain tumours like glioblastoma.
Bismuth-213 Lintuzumab: A Promising Treatment for Acute Myeloid Leukaemia
213Bi-Lintuzumab demonstrated efficacy in AML treatment, offering a targeted approach with manageable side effects, yet development paused.
Bismuth-213 Lintuzumab: A Promising Treatment for Acute Myeloid Leukaemia Read Post »
Bismuth-213 DOTATOC: A Promising Alpha-Labelled Analogue for Tumour Therapy
213Bi-DOTATOC offers potent, targeted alpha therapy for tumours, advancing treatment with precision and reduced systemic toxicity.
Bismuth-213 DOTATOC: A Promising Alpha-Labelled Analogue for Tumour Therapy Read Post »
Precision Cancer Therapy: The Promise of Astatine-211 Parthanatine in High-Risk Neuroblastomas
211At-Parthanatine, targeting PARP1 with alpha radiation, promises precise cancer therapy, especially for high-risk neuroblastomas.
Astatine-211 Sodium Astatide: The Next Generation in Thyroid Disease Treatment
Astatine-211 Sodium Astatide, evolving thyroid treatment, enters trials, promising enhanced precision and safety over traditional Iodine-131 NaI therapy.
Astatine-211 Sodium Astatide: The Next Generation in Thyroid Disease Treatment Read Post »
The Potential of Astatine-211-MX35-F(ab’)2 in Ovarian Cancer Treatment
211At-MX35-F(ab’)2 shows promise in treating ovarian cancer through targeted therapy in ongoing clinical trials.
The Potential of Astatine-211-MX35-F(ab’)2 in Ovarian Cancer Treatment Read Post »
Astatine-211 MABG in Malignant Pheochromocytoma and Paragangliomas
The innovative 211At-MABG targets rare tumours like malignant pheochromocytoma and paragangliomas, promising a new era in treatment.
Astatine-211 MABG in Malignant Pheochromocytoma and Paragangliomas Read Post »
Therapeutic Nuclear Medicine for Advanced Cancer Treatment – Opportunities and Challenges
Therapeutic nuclear medicine leverages radionuclides for targeted cancer treatment, facing challenges in delivery, safety, and regulatory compliance.
Astatine-211 BC8-B10: A Promising Radioimmunoconjugate for Leukaemia Treatment
211At-BC8-B10, targeting CD45 in leukemia, combines BC8 antibody with Astatine-211, showing promising clinical trials.
Astatine-211 BC8-B10: A Promising Radioimmunoconjugate for Leukaemia Treatment Read Post »
Astatine-211 Radiotheranostics: A New Era in Cancer Treatment
Astatine-211 in radiotheranostics offers targeted, effective cancer treatment, but faces production and safety challenges.
Astatine-211 Radiotheranostics: A New Era in Cancer Treatment Read Post »
Astatine-211 81C6-mAb: A Breakthrough in Brain Tumour Treatment with Alpha Radiation
211At-81C6-mAb, targeting tenascin in brain tumours, shows extended survival but needs further funding for development.
Astatine-211 81C6-mAb: A Breakthrough in Brain Tumour Treatment with Alpha Radiation Read Post »
Exploring Actinium-225 RYZ101: A Promising Alpha-Labelled Analogue in Neuroendocrine Tumour Treatment
225Ac-RYZ101 offers promising GEP-NET treatment, targeting tumours with alpha particles via somatostatin receptor-specific edotreotate.
Actinium-225 Rosopatamab: A Breakthrough in Metastatic Prostate Cancer Treatment
225Ac-Rosopatamab, targeting metastatic prostate cancer, combines monoclonal antibodies with alpha radiation, showing promise in early trials.
Actinium-225 Rosopatamab: A Breakthrough in Metastatic Prostate Cancer Treatment Read Post »
Actinium-225 PSMA-617: Revolutionising Prostate Cancer Treatment
225Ac-PSMA-617 revolutionises prostate cancer treatment, offering targeted, effective therapy with promising clinical trial results.
Actinium-225 PSMA-617: Revolutionising Prostate Cancer Treatment Read Post »
Actinium-225 MTI-201: A Promising New Agent in Uveal Melanoma Treatment
225Ac-MTI-201, targeting MC1R, offers groundbreaking, targeted treatment for uveal melanoma with minimal side effects.
Actinium-225 MTI-201: A Promising New Agent in Uveal Melanoma Treatment Read Post »
Actinium-225 Lintuzumab: A Breakthrough in Acute Myeloid Leukaemia Treatment
225Ac-Lintuzumab, targeting CD33, shows promise in AML treatment with potential expansion to other cancers.
Actinium-225 Lintuzumab: A Breakthrough in Acute Myeloid Leukaemia Treatment Read Post »
Actinium-225: The Emerging Star in Targeted Alpha Therapy
Actinium-225 is a rare, promising isotope revolutionizing targeted alpha therapy for various resistant cancers.
Actinium-225: The Emerging Star in Targeted Alpha Therapy Read Post »
Actinium-225 FPI-2265: A Promising Alpha Emitter for Metastatic Castration-Resistant Prostate Cancer Treatment
225Ac-FPI-2265, targeting PSMA, shows promise in treating advanced prostate cancer in the TATCIST clinical trial.
Pioneering Targeted Alpha Therapy: Actinium-225 FPI-2068 and Indium-111 FPI-2107 in Solid Tumours
225Ac-FPI-2068 and 111In-FPI-2107 represent a major advancement in targeted alpha therapy for various solid tumours.
Actinium-225 FPI-2059: Targeted Alpha Therapy in Oncology through NTSR1 Targeting
225Ac-FPI-2059 targets NTSR1 in cancer cells, offering a novel approach in pancreatic cancer treatment.
Actinium-225 FPI-2059: Targeted Alpha Therapy in Oncology through NTSR1 Targeting Read Post »
Actinium-225 FPI-1434 to Target Solid Tumours
225Ac-FPI-1434 advances in clinical trials, targeting IGF-1R in chemo-resistant solid tumors with promising results.
Actinium-225 DOTAZOL Alpharadiotherapy in Bone Diseases with a Focus on Prostate Cancer Treatment
225Ac-DOTAZOL enhances 177Lu-radiotherapy in bone diseases, particularly effective in prostate cancer, as shown in preclinical studies.
Actinium-225 DOTATOC: Transforming GEP-NET Treatment with Targeted Alpha Therapy in Refractory Cases
225Ac-DOTATOC advances GEP-NET treatment, offering targeted, effective therapy for patients resistant to traditional methods.
Actinium-225 DOTA-YS5: A Novel CD46-Targeted Radiopharmaceutical for Prostate Cancer Therapy
225Ac-DOTA-YS5 targets CD46 in prostate cancer, promising precision and effectiveness in therapy.
Exploring the Potential of Actinium-225 DOTA-SP in Targeted Alpha Therapy for Cancer Treatment
225Ac-DOTA-SP, a breakthrough in targeted alpha therapy, offers precise cancer treatment with minimal side effects, revolutionising oncological approaches.